Martin, M., Zielinski, C., Ruiz Borrego, M., Carrasco, E., Turner, N., Ciruelos, E., . . . Gil Gil, M. (2021). Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: A phase III randomised controlled trial—PEARL.
Citación estilo ChicagoMartin, M., et al. Palbociclib in Combination With Endocrine Therapy Versus Capecitabine in Hormonal Receptor-positive, Human Epidermal Growth Factor 2-negative, Aromatase Inhibitor-resistant Metastatic Breast Cancer: A Phase III Randomised Controlled Trial—PEARL. 2021.
Cita MLAMartin, M., et al. Palbociclib in Combination With Endocrine Therapy Versus Capecitabine in Hormonal Receptor-positive, Human Epidermal Growth Factor 2-negative, Aromatase Inhibitor-resistant Metastatic Breast Cancer: A Phase III Randomised Controlled Trial—PEARL. 2021.